Overview
Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease
Status:
Completed
Completed
Trial end date:
2016-11-01
2016-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents. The purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-TNF agent or a different class of medication.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Oslo University HospitalTreatments:
Adalimumab
Certolizumab Pegol
Infliximab
Criteria
Inclusion Criteria:- Patients diagnosed with Inflammatory bowel disease
- Treated with anti-TNF drug
- Follow-up at specialized gastroenterologist in Norway
- Age 18 or over
Exclusion Criteria:
- Patients refusing to participate by not giving their informed consent